NEW YORK, NY / ACCESSWIRE / October 15, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Metagenomi, Inc. ("Metagenomi" or the "Company") (NASDAQ:MGX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
The class action concerns whether Metagenomi and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
You have until November 25, 2024, to ask the Court to appoint you as Lead Plaintiff for the class if you are a shareholder who purchased or otherwise acquired Metagenomi securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.
[Click here for information about joining the class action]
On or around February 9, 2024, Metagenomi conducted its initial public offering ("IPO") of 6.25 million shares of common stock priced at $15.00 per share.
Then, on May 1, 2024, Metagenomi announced that it and Moderna, Inc. had "mutually agreed to terminate their collaboration on primary hyperoxaluria type 1 (PH1)," and that the "rights to develop the PH1 pro-gram, as well as all other rights granted under the collaboration, will be returned [to Metagenomi] as part of the termination."
On this news, Metagenomi's stock price fell $0.87 per share, or 12.36%, to close at $6.17 per share on May 2, 2024.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: Pomerantz LLP